XEOMIN (Clostridium Botulinum neurotoxin type A) - Spasticity of the upper limb

The Committee deems that the clinical benefit of XEOMIN (Clostridium Botulinum neurotoxin type A) proprietary medicinal products is substantial for the symptomatic treatment in adults of spasticity of the upper limb.

The Committee considers that, as with the other medicinal products containing botulinum toxin type A currently available, XEOMIN (Clostridium Botulinum neurotoxin type A) proprietary medicinal products provide no clinical added value (CAV V) in the care pathway for the symptomatic treatment in adults of spasticity of the upper limb.